Kalaris Therapeutics reported positive additional Phase 1a trial data for TH103 in patients with neovascular age-related macular degeneration (wet AMD). With no efficacy/safety magnitude disclosed in the article, this is a modest positive catalyst for the program’s continued development rather than a definitive de-risking event.
Kalaris Therapeutics reported positive additional Phase 1a trial data for TH103 in patients with neovascular age-related macular degeneration (wet AMD). With no efficacy/safety magnitude disclosed in the article, this is a modest positive catalyst for the program’s continued development rather than a definitive de-risking event.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
